Zacks Investment Research
12 May 2026, 14:41 UTC · 24w ago
Verdict
Headline takes no side. We score ZLDPF +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
Zealand Pharma AS (ZLDPF) holds a Zacks Rank #2 (Buy) and a Value grade of A.
More positive than 76% of claims this week
ZLDPF's P/B ratio of 2.16 is significantly lower than its industry average of 3.50.
Continue reading
5 related stories
More positive than 49% of claims this week
ZLDPF's P/S ratio of 2.75 is well below the industry average of 6.48.
So whatLower price-to-sales compared to the sector average indicates potential undervaluation relative to revenue.
More positive than 49% of claims this week
ZLDPF's P/CF ratio of 5.03 is lower than the industry average of 8.92.
So whatBetter cash flow valuation relative to the industry generally supports a more attractive valuation profile.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company is highlighted as a strong value stock with a Zacks Rank #2 (Buy), a Value grade of A, and favorable valuation ratios compared to its industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
19h ago
−38.7%
Price is moving against the score
$33.08 vs $54.00 close before publication (May 11) · not market-adjusted
ZLDPF chart →
